Neurocrine Biosciences' (NBIX) exposure to Food and Drug Administration or tariff-related concerns is relatively less compared with its peers, RBC Capital Markets analyst team said Monday in a research note.
Amid weakness in the broader sector and the analysts' expectations for the company's Ingrezza commercial franchise to remain "relatively solid and durable" in the longer term, the firm notes that the company's stock is trading "well below fundamental fair value" and offers a "buying opportunity."
The team upgraded the stock to outperform from sector perform and slightly reduced the price target to $137 from $138.
Price: 94.93, Change: +4.06, Percent Change: +4.47
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。